VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 1 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2023. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $750,000 | -24.0% | 68,000 | 0.0% | 0.13% | -26.2% |
| Q4 2016 | $987,000 | -40.9% | 68,000 | 0.0% | 0.17% | -42.5% |
| Q3 2016 | $1,669,000 | +21.8% | 68,000 | 0.0% | 0.30% | +17.3% |
| Q2 2016 | $1,370,000 | +349.2% | 68,000 | +2166.7% | 0.26% | +347.4% |
| Q4 2015 | $305,000 | -44.8% | 3,000 | -3.2% | 0.06% | -47.7% |
| Q3 2015 | $553,000 | -19.7% | 3,100 | 0.0% | 0.11% | -5.2% |
| Q2 2015 | $689,000 | +11.9% | 3,100 | 0.0% | 0.12% | +7.5% |
| Q1 2015 | $616,000 | +43.6% | 3,100 | +3.3% | 0.11% | +98.1% |
| Q4 2014 | $429,000 | +8.9% | 3,000 | 0.0% | 0.05% | 0.0% |
| Q3 2014 | $394,000 | +4.2% | 3,000 | 0.0% | 0.05% | -25.0% |
| Q2 2014 | $378,000 | -4.3% | 3,000 | 0.0% | 0.07% | -12.2% |
| Q1 2014 | $395,000 | +12.2% | 3,000 | 0.0% | 0.08% | +331.6% |
| Q4 2013 | $352,000 | +12.5% | 3,000 | 0.0% | 0.02% | -73.6% |
| Q3 2013 | $313,000 | +21.3% | 3,000 | 0.0% | 0.07% | -4.0% |
| Q2 2013 | $258,000 | – | 3,000 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |